Merestinib
Tier C — Watch / tradeMerestinib
Targets：c-Met, AXL, DDR1, DDR2, MKNK1, MKNK2, ROS, Protein-tyrosine kinases, MST1R, FLT3, MerTK, TIE2, Trk-A, Trk-B, Trk-C
Indications (approved)：Bile duct cancer, Metastatic cancer, 高微卫星不稳定性癌症, 皮肤黑色素瘤, Breast cancer, Solid tumour, Pancreatic cancer, Non-small cell lung cancer
Regional status
Synthetic routes & intermediates
Frequently asked questions
What are the approved indications of Merestinib?
Approved indications include: Bile duct cancer, Metastatic cancer, 高微卫星不稳定性癌症, 皮肤黑色素瘤, Breast cancer, Solid tumour, Pancreatic cancer, Non-small cell lung cancer.
When does the Merestinib patent expire?
No public expiry year is available for Merestinib yet; this page updates once verified.
How do I get a quote for Merestinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-10